B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28

被引:929
作者
AZUMA, M
ITO, D
YAGITA, H
OKUMURA, K
PHILLIPS, JH
LANIER, LL
SOMOZA, C
机构
[1] UNIV TOKYO,FAC MED,DEPT ORAL & MAXILLOFACIAL SURG,BUNKYO KU,TOKYO 113,JAPAN
[2] DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304
关键词
D O I
10.1038/366076a0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
THE membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes3. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex4,5. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.
引用
收藏
页码:76 / 79
页数:4
相关论文
共 24 条
[1]   MOLECULAR-CLONING OF A CD28 CDNA BY A HIGH-EFFICIENCY COS CELL EXPRESSION SYSTEM [J].
ARUFFO, A ;
SEED, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) :8573-8577
[2]   CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T [J].
AZUMA, M ;
CAYABYAB, M ;
BUCK, D ;
PHILLIPS, JH ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :353-360
[3]  
AZUMA M, 1992, J IMMUNOL, V149, P1115
[4]  
AZUMA M, 1993, J IMMUNOL, V150, P2091
[5]   FUNCTIONAL EXPRESSION OF B7/BB1 ON ACTIVATED LYMPHOCYTES-T [J].
AZUMA, M ;
YSSEL, H ;
PHILLIPS, JH ;
SPITS, H ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) :845-850
[6]   A NEW MEMBER OF THE IMMUNOGLOBULIN SUPERFAMILY - CTLA-4 [J].
BRUNET, JF ;
DENIZOT, F ;
LUCIANI, MF ;
ROUXDOSSETO, M ;
SUZAN, M ;
MATTEI, MG ;
GOLSTEIN, P .
NATURE, 1987, 328 (6127) :267-270
[7]  
DOMLO NK, 1991, EUR J IMMUNOL, V21, P1277
[8]   SELECTIVE INDUCTION OF B7/BB-1 ON INTERFERON-GAMMA STIMULATED MONOCYTES - A POTENTIAL MECHANISM FOR AMPLIFICATION OF T-CELL ACTIVATION THROUGH THE CD28 PATHWAY [J].
FREEDMAN, AS ;
FREEMAN, GJ ;
RHYNHART, K ;
NADLER, LM .
CELLULAR IMMUNOLOGY, 1991, 137 (02) :429-437
[9]  
FREEMAN GJ, 1989, J IMMUNOL, V143, P2714
[10]   CD48 IS A COUNTER-RECEPTOR FOR MOUSE CD2 AND IS INVOLVED IN T-CELL ACTIVATION [J].
KATO, K ;
KOYANAGI, M ;
OKADA, H ;
TAKANASHI, T ;
WONG, YW ;
WILLIAMS, AF ;
OKUMURA, K ;
YAGITA, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (05) :1241-1249